INVESTOR PRESENTATION 2019 - Better Data, Better Health - TSX-V: AVCR OTCQB: AVCRF
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
TSX-V: AVCR
OTCQB: AVCRF
INVESTOR PRESENTATION 2019
Better Data, Better Health
WHO ARE
WE?
Avricore is a total health innovator capitalizing on
technological advancements and consumer health
trends, offering consumers, health providers and life-
science companies the ability to take control of both
spending and health outcomes.
We intend on become the world’s largest health data
company and are utilizing point-of-care technologies
within community pharmacy to achieve this.
www.avricorehealth.com
QUICK OVERVIEW
➤ Converted from VANC Pharmaceuticals, a generic drug maker
with 91 generic offerings in 2018 to become Avricore Health Inc.
➤ We maintain the ownership of these dormant licences.
➤ Avricore is currently selling Hema-fer, an OTC iron supplement, to
pharmacies across Canada.
➤ In the transition, Avricore purchased two technologies, the
Avricore Platform (formerly Corozon Platform) and HealthTab.
➤ The Company’s primary focus today is on developing a network
of point-of-care analyzers that utilizes its HealthTab software in
community pharmacy.
W E L C O M E T O H E A LT H TA B A N D
THE RASTR MODEL
Patient consent Personalized
Reports
De-identified
Realtime Data
The patient driven rapid access, safety test reporting system (RASTR)
Turnkey System
2 panels, 21 results
In-store kiosk Lab-accurate analyzer Secure online results
• Proven point-of-care screening system,
designed to support pharmacists evolving
role.
• Empowers patients to be proactive about
their health by directly measuring and
monitoring key safety tests and
biomarkers of chronic disease.
• Simple, fast, lab-accurate, and requires
just a few drops of blood from a finger
stick.
• Results can be printed in-store or
accessed securely online.
• Watch short video here and visit our
HealthTab website.
•
RASTR MODEL • A network of HealthTab systems utilizing the Piccolo Analyzer in community pharmacies. • Running panels on consumers utilizing finger stick sample, monitoring up to 21 key bio-markers, and/or customizable tests. • Allows for API integration for better data flow and customization. • Provides harmonized, real-time data on consumer health. 1. The client purchases the drug or other health product. 2. The pharmacy leases the analyzers at a reasonable cost to become a part of the network. 3. The drug maker pays to access the network and sponsors test fees for consumer.
OUR TEAM
Bob Rai - CEO & director Dr. Robert Sindelar - Director
BOARD DIRECTORS David Hall - Chairman & Director David Farnfield – Director
Alan Arnstein - Director
Ray Chepsiuk – Board Advisor Mark Zhou – Board Advisor
BOARD ADVISORS Sherif Guorgui - Board Advisor
Philippe Ungat – Board Advisor
David Huston- Board Advisor
Kevin Strong - CFO
Rodger Seccombe - Head of HealthTab Division
MANAGEMENT
Deena Siblock - Corporate Secretary
Hector Bremner – EVP, Strategic Communications/Public Affairs
For more information on our team, please visit our website
PROJECTIONS
Annual Sales
('000 CAD)
18,000
16,000
14,000
12,000
10,000
8,000
6,000
4,000
2,000
-
2019 2020 2021 2022 2023 2024 2025
Annual Cash-Flow
('000 CAD)
12,000
10,000
8,000
6,000
4,000
2,000
-
2019 2020 2021 2022 2023 2024 2025
(2,000)
PROJECTIONS
Our business model presents an exciting opportunity for investment. Cash flows and revenues
are consistent with manageable expense loads.
Equity
3,900
Investment
CFs (before-tax) (3,900) - 1,117 7,453 9,539 9,791 10,509 10,688 10,688 10,688 10,688
CFs (after-tax) (3,900) - 1,096 5,933 7,432 7,404 7,992 8,120 8,096 8,086 8,081
Before tax
IRR 78%
NPV 29,902
After tax
IRR 68%
NPV 22,211CAP STRUCTURE
As at January 7, 2019
Includes shares issued to date as per the Lampyon agreement, the Healthtab Agreement, and the Corozon Agreement (please note: 681,818 of
the Corozon shares are subject to a year hold, expiring on May 18, 2019).
** Does not include remaining shares to be issued pursuant to the Lampyon agreement, as these shares are based on calculating the volume
weighed average closing share price on the last 5 trading days preceding the date of issue
Common Shares Issued & Outstanding (per Computershare Report - 45,620,219
January 7, 2019)
Reserved for Stock Options 2,566,072
Reserved for Warrants @ $0.20 - Expiry Jun 26, 2022 1,791,159
Reserved for Finders Warrants @ $0.20 - Expiry Jun 26, 2022 - All warrants -
have beenfor
Reserved exercised.
Warrants @ $0.20 - Expiry Aug 3, 2022 742,667
Reserved for Warrants @ $0.20 - Expiry Nov 27, 2022 2,850,000
Reserved for Finders Warrants @ $0.20 - Expiry Nov 27, 2022 22,000
Reserved for Emerald Warrants @ $0.33 (Supply & Distribution Agreement) 3,030,303
-Reserved
Expiry April
for 15, 2020 @ $0.33 - Expiry Jul 31, 2020
Warrants 5,327,335
Reserved for Finders Warrants @ $0.33 - Expiry Jul 31, 2020 88,800
TOTAL 62,038,555OUR PARTNERS
JOIN US IN REALIZING THIS OPPORTUNITY Avricore Health is seeking to secure 40 Piccolo Xpress analyzers and expand the RASTR network in the immediate future. The company has no competition in this field, yet. However, as we have demonstrated here, the POCT market is rapidly growing as established health data methods get “smart.” To learn more about how you can invest in the growth of this technology, or partner with us to test your consumers, please contact us at: investor@avricorehealth.com
You can also read
